1. Home
  2. STTK vs DQ Comparison

STTK vs DQ Comparison

Compare STTK & DQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$5.65

Market Cap

652.4M

Sector

Health Care

ML Signal

HOLD

Logo DAQO New Energy Corp.

DQ

DAQO New Energy Corp.

HOLD

Current Price

$11.17

Market Cap

692.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
DQ
Founded
2016
2006
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
652.4M
692.2M
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
STTK
DQ
Price
$5.65
$11.17
Analyst Decision
Strong Buy
Buy
Analyst Count
12
7
Target Price
$15.40
★ $17.91
AVG Volume (30 Days)
★ 1.2M
434.7K
Earning Date
11-09-2026
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 53.02
N/A
EPS
N/A
★ N/A
Revenue
★ $1,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$73.98
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.72
$9.89
52 Week High
$8.33
$36.59

Technical Indicators

Market Signals
Indicator
STTK
DQ
Relative Strength Index (RSI) 44.67 53.12
Support Level $5.19 $9.89
Resistance Level $6.00 $11.28
Average True Range (ATR) 0.36 0.43
MACD 0.04 0.13
Stochastic Oscillator 43.49 85.14

Price Performance

Historical Comparison
STTK
DQ

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About DQ DAQO New Energy Corp.

Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.

Share on Social Networks: